Inhibitex to Present at the 2010 Deutsche Bank BioFEST Conference on Tuesday, December 14th

ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (Nasdaq: INHX) today announced that Russell H. Plumb, president and chief executive officer, will present an overview of the company and its pipeline of differentiated antiviral compounds at the Deutsche Bank BioFEST Conference December 14, 2010 at 2:35 PM (ET). The conference is being held at The Four Seasons Hotel in Boston, MA. The presentation will be simultaneously webcast and can be accessed by visiting the Investors section of the Inhibitex website at www.inhibitex.com. Shortly following the live webcast, a replay will also be available on the Company website.

About Inhibitex

Inhibitex, Inc., a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit www.inhibitex.com.

Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.



CONTACT:

Inhibitex, Inc.
Russell H. Plumb, Chief Executive Officer, 678-746-1136
[email protected]
or
The Trout Group
Lee M. Stern, CFA, 646-378-2922
[email protected]

KEYWORDS:   United States  North America  Georgia  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.